Greenyn Biotechnology Co (ROCO:6846) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Greenyn Biotechnology Co EBITDA Margin % Related Terms
Greenyn Biotechnology Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6846 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Greenyn Biotechnology Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Greenyn Biotechnology Co EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Greenyn Biotechnology Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Greenyn Biotechnology Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Greenyn Biotechnology Co (ROCO:6846) has a EBITDA Margin % of 28.36% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Greenyn Biotechnology Co and its competitors. This is near median its historical median of 27.51. Over the past decade, Greenyn Biotechnology Co's EBITDA Margin % has ranged from 24.03 to 29.83. According to the industry distribution chart, Greenyn Biotechnology Co ranks #125 out of 943 companies in the Biotechnology industry, placing it in the top 13.3%.
Is Greenyn Biotechnology Co's EBITDA Margin % too high?
Greenyn Biotechnology Co's current EBITDA Margin % of 28.36% is near median its 10-year median of 27.51. Over the past 10 years, this metric has ranged from a low of 24.03 to a high of 29.83. Based on the distribution chart, Greenyn Biotechnology Co ranks #125 out of 943 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Greenyn Biotechnology Co has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Greenyn Biotechnology Co's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Greenyn Biotechnology Co ranks #125 out of 943 companies for EBITDA Margin %. This places Greenyn Biotechnology Co in the top 13% of its industry — outperforming the majority of peers. Historically, Greenyn Biotechnology Co's own EBITDA Margin % has ranged from 24.03 to 29.83 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Greenyn Biotechnology Co and its competitors. Greenyn Biotechnology Co's current EBITDA Margin % is 28.36%, which is near median its own 10-year median of 27.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Greenyn Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Greenyn Biotechnology Co (ROCO:6846) is currently considered Fairly Valued. The stock's GF Value™ is NT$66.84, compared to a current price of NT$63.70 — trading 4.7% below its estimated fair value. The current EBITDA Margin % is 28.36%, which is near median its 10-year median of 27.51. Greenyn Biotechnology Co's overall GF Score™ is 65/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Greenyn Biotechnology Co (ROCO:6846), the current EBITDA Margin % is 28.36% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Greenyn Biotechnology Co (ROCO:6846) Overvalued in 2026?
Based on GuruFocus' analysis, Greenyn Biotechnology Co stock appears to be undervalued.
The current stock price of NT$63.70 is trading 4.7% below its estimated GF Value™ of NT$66.84.
GuruFocus considers Greenyn Biotechnology Co to be Fairly Valued.
Key valuation signals for ROCO:6846:
EBITDA Margin %: 28.36% (near median its 10-year median of 27.51)
GF Value™: NT$66.84 vs. price of NT$63.70 (4.7% below fair value)
No single metric tells the full story. See the ROCO:6846 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Greenyn Biotechnology Co Ltd is engaged in the business of health food raw materials production and sales of raw materials and production and sales of formula preparation.
65GF Score
Get the complete analysis for ROCO:6846
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6846 has been successfully added to your 
